Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jan 23, 2024 3:30pm
348 Views
Post# 35841512

Company buyout price vs share price.

Company buyout price vs share price.

I have written to this issue a few times. & as others have acknowledged, the buyout price of a company has. ZERO, to do with the trading shareprice.
Yes the # gets accociated as a multiple of SP at news time. Nice simple comparable.
However not in any way related to the negotiations.
As a buyer of ONC for example. The price would need to be justified internally at the aquiring company.
In simple math, what could owning Onc, its patents, the potential future income from co- therapy with the aquiring company,s drugs etc.
In a perfect world that math would be easy. Number of patients x treatment price = potential annual income. What is the required financial outlay to just that income.
That would be the case with an approved marketable product.
Pre- approval, adds in mutiple layers of doubt. Those who take the time to read analysts reports see those " discount" rates used in their numbers.
So who decides?
In negotiations, both sides have internal reporting requirements. All meetings & discsions are documented.
As well a third party " fair price evaluation" would be undertaken.
That report would form part of any agreement, placed out for shareholders approval.
why?
Obviously, after the fact it would be easy ( has happened), shaeholders of either side launch a class action. Being sold for too little, or bought for too much.
Point being & you can find a great explanation on investopedia, " value of biotech companies"
People like to say Matt wants this or that. True!
However, in a buyout situation, the B.O.D. Has final say not operating management.
Why, do these things take so long?
I have been part of no less than 6 companies taken over.
The voting package includes negotiations details, up to & including when talks first started.
Assuming Roche decided they wanted to own Onc. 

Upfront talks would happen. Leading to a NDA. Then accountants, lawyers & clinical advisors get involved.
Once a reasonable decision is made, an outside consultant would be brought in to provide audited, validated opinion of valuation.
The negotiations would Center around that.
At no time in any of those calculations does the trading share price come into discussion.
onc value would be based on future income to the aquiring company.
Could Onc be bought out for mutiple billions?
100% depends on the potential oF income from Pela.
nothing more , nothing less.

When they talked about de- risking. There are financial as well as clinical implications from trial certainty.
in any business " doubt = discount"
Longer & additional trial results remove various doubts. It takes longer, but if positive greatly increases what an aquiring company is willing to pay.
Both companies need to justify a final negotiated price....backed with documents, valuation reports & third party opinions.
All available at voting time.
Stay tuned.





 

<< Previous
Bullboard Posts
Next >>